Caribou Biosciences Inc., a biotechnology company, has announced that it has regained compliance with Nasdaq's listing requirements. The company received a Compliance Notice from Nasdaq on June 18, 2025, indicating that it now meets the Nasdaq Global Select Market's minimum closing bid price of $1.00 per share. This development follows a period from June 3 to June 17, 2025, during which the company's stock consistently maintained this minimum price threshold. As a result, Caribou Biosciences is no longer at risk of delisting and continues to be listed on the Nasdaq exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.